Evidence map›Paper›PMID 36004356›Full record

ArticleFrontiers in endocrinology2022

Prediction models constructed for Hashimoto's thyroiditis risk based on clinical and laboratory factors.

Peng Li, Fang Liu, Minsu Zhao, Shaokai Xu, Ping Li, Jingang Cao, Dongming Tian, Yaopeng Tan, Lina Zheng, Xia Cao and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Peng LiDepartment of Breast Surgery, Xuchang Central Hospital, Xuchang, China.
Fang LiuHealth Management Center, Kaifeng Central Hospital, Kaifeng, China.
Minsu ZhaoDepartment of Endocrinology, Jincheng People's Hospital, Jincheng City, China.
Shaokai XuDepartment of Breast Surgery, Xuchang Central Hospital, Xuchang, China.
Ping LiDepartment of Breast Surgery, Xuchang Central Hospital, Xuchang, China.
Jingang CaoDepartment of Breast Surgery, Xuchang Central Hospital, Xuchang, China.
Dongming TianDepartment of Breast Surgery, Xuchang Central Hospital, Xuchang, China.
Yaopeng TanDepartment of Breast Surgery, Xuchang Central Hospital, Xuchang, China.
Lina ZhengHealth Management Center, Kaifeng Central Hospital, Kaifeng, China.
Xia CaoHealth Management Center, Kaifeng Central Hospital, Kaifeng, China.
Yingxia PanDepartment of Medicine, Shanghai Biotecan Pharmaceuticals Co., Ltd., Shanghai, China.
Hui TangDepartment of Medicine, Shanghai Biotecan Pharmaceuticals Co., Ltd., Shanghai, China.
Yuanyuan WuDepartment of Medicine, Shanghai Biotecan Pharmaceuticals Co., Ltd., Shanghai, China.
Yi SunDepartment of Breast Surgery, Xuchang Central Hospital, Xuchang, China.
Xuchang University · CNBiota Pharmaceuticals (United States) · USKaifeng University · CNXuzhou Central Hospital · CNZoucheng People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hashimoto's thyroiditis (HT) frequently occurs among autoimmune diseases and may simultaneously appear with thyroid cancer. However, it is difficult to diagnose HT at an early stage just by clinical symptoms. Thus, it is urgent to integrate multiple clinical and laboratory factors for the early diagnosis and risk prediction of HT. Methods: We recruited 1,303 participants, including 866 non-HT controls and 437 diagnosed HT patients. 44 HT patients also had thyroid cancer. Firstly, we compared the difference in thyroid goiter degrees between controls and patients. Secondly, we collected 15 factors and analyzed their significant differences between controls and HT patients, including age, body mass index, gender, history of diabetes, degrees of thyroid goiter, UIC, 25-(OH)D, FT3, FT4, TSH, TAG, TC, FPG, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol. Thirdly, logistic regression analysis demonstrated the risk factors for HT. For machine learning modeling of HT and thyroid cancer, we conducted the establishment and evaluation of six models in training and test sets. Results: The degrees of thyroid goiter were significantly different among controls, HT patients without cancer (HT-C), and HT patients with thyroid cancer (HT+C). Most factors had significant differences between controls and patients. Logistic regression analysis confirmed diabetes, UIC, FT3, and TSH as important risk factors for HT. The AUC scores of XGBoost, LR, SVM, and MLP models indicated appropriate predictive power for HT. The features were arranged by their importance, among which, 25-(OH)D, FT4, and TSH were the top three high-ranking factors. Conclusions: We firstly analyzed comprehensive factors of HT patients. The proposed machine learning modeling, combined with multiple factors, are efficient for thyroid diagnosis. These discoveries will extensively promote precise diagnosis, personalized therapies, and reduce unnecessary cost for thyroid diseases.

Indexed as

GoiterHashimoto DiseaseThyroid NeoplasmsCholesterolHumansThyrotropinCholesterolThyrotropinHashimoto’s thyroiditismachine learning modelingprecise diagnosisrisk factorsthyroid cancer

Identifiers

PMID36004356
PMCPMC9393718
OpenAlexW4290614118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.